Sven Walderich, MD
Fellow
Medicine
School of Medicine
Education & Training
Show all (2) Hide
- M.D. Weill Cornell Medicine 04/2020
- B.S. Biochemistry and Molecular Biology University of California, Santa Barbara 06/2015
Interests
Show all (5) Hide
- Pulmonary and Critical Care
- Global Health
- Oncology
- Infectious Diseases
- Medical Education
Publications (5)
Top publication keywords:
Folate Receptor 1Blood ProteinsNuclear ProteinsAntibodies, MonoclonalDNA HelicasesMembrane ProteinsGalectinsCA-125 AntigenSepsisTranscription FactorsTumor MicroenvironmentEpigenesis, GeneticCancer VaccinesFluid TherapyOvarian Neoplasms
-
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
Science advances 2024 Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche RP, Qu R, Rosenberg L, Hamard PJ, Bykov Y, Green H, Gusain L, Chiappinelli KB, Ozsoy MA, Chui MH, Basili T, Gardner R, Walderich S, … -
Associations Between Volume of Early Intravenous Fluid and Hospital Outcomes in Septic Patients With and Without Heart Failure: A Retrospective Cohort Study.
Critical care explorations 2024 Beagle AJ, Prasad PA, Hubbard CC, Walderich S, Oreper S, Abe-Jones Y, Fang MC, Kangelaris KN -
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
bioRxiv : the preprint server for biology 2023 Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche R, Qu R, Hamard PJ, Bykov Y, Green H, Chiappinelli KB, Ozsoy MA, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, Gönen M,… -
Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies.
Scientific reports 2021 Stasenko M, Smith E, Yeku O, Park KJ, Laster I, Lee K, Walderich S, Spriggs E, Rueda B, Weigelt B, Zamarin D, Rao TD, Spriggs DR -
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
Journal for immunotherapy of cancer 2020 Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, Li Y, Hollmann TJ, Grisham RN, Erskine CL, Block MS, Knutson KL, O'Cearbhaill…